A clinical study on the efficacy of hydroxyapatite - Bioactive glass composite granules in the management of periodontal bony defects

Abstract

Background:In periodontal regeneration, several alloplastic materials are being used with a goal to reconstruct new osseous tissue in the infrabony defect sites. The present study was undertaken to evaluate the efficacy of hydroxyapatite–bioactive glass (HA:BG) composite granules in the management of periodontal bony defects.Materials and Methods:A randomized control study was conducted. Subjects with infrabony defects were divided into three groups. Test Group 1 (n = 10): Defect site was treated with HA:BG, with a biodegradable membrane. Test Group 2 (n = 10): Defect site was treated with HAP, with a biodegradable membrane. Control group (n = 10): Defect site was treated with open flap debridement with a biodegradable membraneResults:The healing of defects was uneventful and free of any biological complications. The gain in clinical attachment level, reduction of probing pocket depth, and defect fill were statistically significant in all three groups. TG1 sites showed significant defect fill than TG2 and CG sites.Conclusion:The performance of HA:BG was better compared to HAP and open flap debridement for the reconstruction of infrabony defects.

The use of hydroxyapatite bone substitute grafting for alveolar ridge preservation, sinus augmentation, and periodontal bone defect: A systematic review

“…For periodontal bone defects ( Table 6 ), 20 studies involving RCTs [ 10 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 ] and prospective CCTs [ 9 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 ] reported a parallel [ 79 , 84 , 87 ] or split mouth [ 10 , 81 , 83 , 86 ] design. The study population consisted of 12–263 persons (age, 14–75 years) divided into two to four study groups with a follow-up of 1–24 months after grafting.…”

“…The study population consisted of 12–263 persons (age, 14–75 years) divided into two to four study groups with a follow-up of 1–24 months after grafting. The outcome measures were analyzed radiographically by Intraoral Periapical (IOPA) [ 10 , 78 ], CT [86] , long cone-paralleling technique [ 80 , 85 , 91 , 94 ], computer assisted densitometry image analysis (CADIA) [87] , and other radiographic methods [ 9 , 79 , 81 , 82 , 83 , 88 , 89 , 92 , 93 ].…”

“…The control groups underwent open flap debridement (OFD) [ 9 , 10 , 78 , 79 , 80 , 81 , 82 , 86 , 88 , 89 ], demineralized freeze-dried bone allografts (DFDBA) [ 87 , 91 ], bovine bone [83] , barrier membrane (Goretex) [90] , enamel matrix derivative (EMD) [ 77 , 84 ], nonabsorbable polytetrafluoroethylene membrane (e-PTFE) [85] , and debridement only (DEBR) [93] . The test groups were alloplastic graft alone with β-tricalcium phosphate (β-TCP/HA) [77] and bonelike containing glass-reinforced HA [86] , synthetic HA alone [93] , porous HA (PHA) [90] , resorbable HA (Osteogen) [66] , or synthetic HA combined with OFD [ 9 , 78 , 88 , 89 ], PRP [78] , β-TCP [ 80 , 81 , 82 ], barrier membrane such as EMD [ 81 , 84 ], collagen membrane [79] , Goretex [90] , e-PTFE membrane [94] , bioactive glass [10] , or DFDBA [92] . The mean values and 95% CIs for the test and control groups of the selected comparable studies performed for treatment of periodontal bone defect measured in certain follow-up periods ( Fig.…”

“…Therefore, bone surgery is performed to regenerate the lost bone and restore the alveolar ridge contour. Several grafting materials are used during surgery [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ].…”

What is the Proper Sample Size for Studies of Periodontal Treatment?

“…For some outcomes, consistent distributional consensus may not be found. For example, the distribution of clinical attachment loss can be moderately skewed to the right (Figure 2 in Rosenberg and colleagues 18 ), fairly symmetric ( Figure 1 in Zuza and colleagues 19 ), or irregular without a specific trend (Box plot 2 in Debnath and colleagues 20 ). These different trends of the distribution of clinical attachment may be due to small sample sizes or different treatment/patient characteristics.…”